Limits...
Main considerable factors for correct laboratory test interpretation under DOA treatment.

Mani H, Lindhoff-Last E - Thromb J (2013)

Bottom Line: To avoid misinterpretation and mismanagement clinicians should be aware of the interference of new direct oral anticoagulants (DOA) on coagulation assays.A variety of oral anticoagulants targeting specific coagulation factors has already entered the market, and new indications for DOA will be released each year over the next few years.Due to their heterogeneous mode of action and different pharmacokinetic profile each DOA will vary in its effects on coagulations assays, and it is of current importance to recognize these variable effects.In this summary the main considerable factors for correct laboratory test interpretation under DOA treatment are described.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Internal Medicine, Division of Vascular Medicine and Hemostaseology, Johann Wolfgang Goethe-University Hospital, Frankfurt/Main, Germany. Helen.Mani@kgu.de.

ABSTRACT

Summary: To avoid misinterpretation and mismanagement clinicians should be aware of the interference of new direct oral anticoagulants (DOA) on coagulation assays. A variety of oral anticoagulants targeting specific coagulation factors has already entered the market, and new indications for DOA will be released each year over the next few years. Due to their heterogeneous mode of action and different pharmacokinetic profile each DOA will vary in its effects on coagulations assays, and it is of current importance to recognize these variable effects.In this summary the main considerable factors for correct laboratory test interpretation under DOA treatment are described.

No MeSH data available.


Related in: MedlinePlus

Effect of dabigatran and rivaroxaban on the prothrombin time in dependence of drug administration and thromboplastin reagent.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3842690&req=5

Figure 3: Effect of dabigatran and rivaroxaban on the prothrombin time in dependence of drug administration and thromboplastin reagent.

Mentions: Rivaroxaban and apixaban as selective direct inhibitors of factor Xa, inhibit prothrombinase-bound factor Xa. Since the PT assay is sensitive to the prothrombinase complex, the PT is influenced by direct factor Xa inhibitors of factor Xa, whereas dabigatran in low doses has little effect on PT (Figure3).


Main considerable factors for correct laboratory test interpretation under DOA treatment.

Mani H, Lindhoff-Last E - Thromb J (2013)

Effect of dabigatran and rivaroxaban on the prothrombin time in dependence of drug administration and thromboplastin reagent.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3842690&req=5

Figure 3: Effect of dabigatran and rivaroxaban on the prothrombin time in dependence of drug administration and thromboplastin reagent.
Mentions: Rivaroxaban and apixaban as selective direct inhibitors of factor Xa, inhibit prothrombinase-bound factor Xa. Since the PT assay is sensitive to the prothrombinase complex, the PT is influenced by direct factor Xa inhibitors of factor Xa, whereas dabigatran in low doses has little effect on PT (Figure3).

Bottom Line: To avoid misinterpretation and mismanagement clinicians should be aware of the interference of new direct oral anticoagulants (DOA) on coagulation assays.A variety of oral anticoagulants targeting specific coagulation factors has already entered the market, and new indications for DOA will be released each year over the next few years.Due to their heterogeneous mode of action and different pharmacokinetic profile each DOA will vary in its effects on coagulations assays, and it is of current importance to recognize these variable effects.In this summary the main considerable factors for correct laboratory test interpretation under DOA treatment are described.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Internal Medicine, Division of Vascular Medicine and Hemostaseology, Johann Wolfgang Goethe-University Hospital, Frankfurt/Main, Germany. Helen.Mani@kgu.de.

ABSTRACT

Summary: To avoid misinterpretation and mismanagement clinicians should be aware of the interference of new direct oral anticoagulants (DOA) on coagulation assays. A variety of oral anticoagulants targeting specific coagulation factors has already entered the market, and new indications for DOA will be released each year over the next few years. Due to their heterogeneous mode of action and different pharmacokinetic profile each DOA will vary in its effects on coagulations assays, and it is of current importance to recognize these variable effects.In this summary the main considerable factors for correct laboratory test interpretation under DOA treatment are described.

No MeSH data available.


Related in: MedlinePlus